# DFP-14927

Source: https://onco.cc/drugs/dfp-14927/  
OnCo record `dfp-14927` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DFP-14927 is an experimental PEGylated polymer conjugate of the nucleoside analogue DFP-10917 from Delta-Fly Pharma, in phase 1 trials for advanced solid tumours.

## Summary

DFP-14927 is a PEGylated polymer conjugate of the nucleoside analogue DFP-10917 from Delta-Fly Pharma. A large four-arm PEGylated form of DFP-10917 designed for once-weekly dosing. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT03943004 in advanced solid tumours, registry status RECRUITING. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: DFP-14927
- Modality: PEGylated polymer conjugate of the nucleoside analogue DFP-10917
- Mechanism: A large four-arm PEGylated form of DFP-10917 designed for once-weekly dosing.

## Sources

- Delta-Fly Pharma: delta-flypharma.co.jp: https://www.delta-flypharma.co.jp/en/r-and-d
- Delta-Fly Pharma: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT03943004
- ClinicalTrials.gov: trials of DFP-14927: https://clinicaltrials.gov/search?intr=DFP-14927

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Delta-Fly Pharma](https://onco.cc/companies/delta-fly-pharma/)
- trials: [Trial of DFP-14927 in Advanced Solid Tumors](https://onco.cc/trials/nct03943004/)

---
JSON: https://onco.cc/api/v1/entities/dfp-14927.json